Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pain and opioid use in chronic liver disease: optimal treatment must address the mental health care needs of the patient.

Literature DB >> 23959213

Pain and opioid use in chronic liver disease: optimal treatment must address the mental health care needs of the patient.

Jennifer M Loftis, Peter Hauser.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Analgesics, Opioid

Year: 2013 PMID： 23959213 PMCID： PMC4415603 DOI： 10.1007/s10620-013-2809-4

Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199

× No keyword cloud information.

21 in total

1. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy.

Authors: Sinead M O'Brien; Paul Scully; Peter Fitzgerald; Lucinda V Scott; Timothy G Dinan
Journal: J Psychiatr Res Date: 2006-07-25 Impact factor: 4.791

Review 2. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review.

Authors: D A Fishbain; R Cutler; H L Rosomoff; R S Rosomoff
Journal: Clin J Pain Date: 1997-06 Impact factor: 3.442

3. Integrated hepatitis C virus treatment: addressing comorbid substance use disorders and HIV infection.

Authors: Marilyn S Huckans; Aaron D Blackwell; Todd A Harms; David W Indest; Peter Hauser
Journal: AIDS Date: 2005-10 Impact factor: 4.177

4. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care.

Authors: Marian Fireman; David W Indest; Aaron Blackwell; Ashlee J Whitehead; Peter Hauser
Journal: Clin Infect Dis Date: 2005-04-15 Impact factor: 9.079

5. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion.

Authors: M Maes; C Song; A H Lin; S Bonaccorso; G Kenis; R De Jongh; E Bosmans; S Scharpé
Journal: Neuropsychopharmacology Date: 1999-04 Impact factor: 7.853

Review 6. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

Authors: Jennifer M Loftis; Annette M Matthews; Peter Hauser
Journal: Drugs Date: 2006 Impact factor: 9.546

7. Pain, substance use disorders and opioid analgesic prescription patterns in veterans with hepatitis C.

Authors: Ashlee J Whitehead; Steven K Dobscha; Benjamin J Morasco; Samantha Ruimy; Cara Bussell; Peter Hauser
Journal: J Pain Symptom Manage Date: 2008-03-20 Impact factor: 3.612

Review 8. The biopsychosocial approach to chronic pain: scientific advances and future directions.

Authors: Robert J Gatchel; Yuan Bo Peng; Madelon L Peters; Perry N Fuchs; Dennis C Turk
Journal: Psychol Bull Date: 2007-07 Impact factor: 17.737

9. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha.

Authors: Jennifer M Loftis; Marilyn Huckans; Samantha Ruimy; David J Hinrichs; Peter Hauser
Journal: Neurosci Lett Date: 2007-11-06 Impact factor: 3.046

Pain and opioid use in chronic liver disease: optimal treatment must address the mental health care needs of the patient.

1. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy.

Review 2. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review.

3. Integrated hepatitis C virus treatment: addressing comorbid substance use disorders and HIV infection.

4. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care.

5. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion.

Review 6. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

7. Pain, substance use disorders and opioid analgesic prescription patterns in veterans with hepatitis C.

Review 8. The biopsychosocial approach to chronic pain: scientific advances and future directions.

9. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha.

10. A closer look at pain and hepatitis C: preliminary data from a veteran population.

1. Health related management plans improve sleep disorders of patients with chronic liver disease.

Review 2. Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications.

3. Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease.

4. The assessment and management of pain in cirrhosis.